Recently, Shanghai plans to set up three industrial pilot funds with a total scale of 89 billion yuan, of which 21.5 billion yuan will be invested in the field of biomedicine - innovative drugs and high-end preparations, high-end medical devices, biotechnology, high-end pharmaceutical equipment and other fields.

Focus on integrated circuits, biomedicine, artificial intelligence three leading industries

The three pilot funds are: 22.5 billion yuan of artificial intelligence fund (tentative name), investing in intelligent chips, intelligent software, autonomous driving, intelligent robots and other fields; A biopharmaceutical fund of 21.5 billion yuan (tentative name) will be invested in innovative drugs and high-end preparations, high-end medical devices, biotechnology, high-end pharmaceutical equipment and other fields; And 45 billion yuan of integrated circuit fund (tentative name), invested in chip design, manufacturing and sealing, equipment materials and parts and other fields.

Among them, Shanghai Guojing plans to invest a total of 40 billion yuan, ranking first; Shanghai Pudong plans to invest 13.75 billion yuan; Guotai Junan and Haitong Securities, the two institutions each plan to invest 1 billion yuan.

Relevant data show that the amplification effect of government-guided mother funds on social capital can reach 4.5 times, that is to say, through the 100 billion yuan of mother funds, Shanghai may drive more than 400 billion funds to invest in the above three industries in the future. The tax revenue it can bring to the regional government, the corresponding industrial capital landing amount, and the total GDP are very considerable.

Not only Shanghai, but all over the country are increasing investment in biomedical health. On June 20, four funds were registered in Beijing, with a total scale of 50 billion yuan: Among them, the Beijing Pharmaceutical and Health Industry Investment Fund (20 billion yuan), the Beijing robot Industry Development Investment Fund (10 billion yuan), the Beijing information Industry Development Investment Fund (10 billion yuan), and the Beijing Artificial Intelligence Industry Investment Fund (10 billion yuan), with a total investment scale of 50 billion yuan.

$21.5 billion biomedical Fund, Who will benefit?

Biomedicine is one of the three leading industries in Shanghai, and accelerating the construction of an innovative highland of biomedicine industry with global influence is an important part of Shanghai's construction of an international science and technology innovation center.

Data show that in 2023, the scale of Shanghai's biopharma industry exceeded 900 billion yuan, an increase of 4.9%. In the past five years, Shanghai accounted for more than 1/3 of the overseas authorization projects of new drugs with a transaction amount of more than 500 million US dollars, and at present, the only two foreign-funded enterprises in the country have priority over the global listing of drugs from Shanghai. At present, Shanghai occupies 3 out of 5 cell therapy products in China; In the clinical approval of immune cell therapy, Shanghai accounts for 1/3 of the country, gene therapy clinical approval accounts for 1/4 of the country, and stem cell therapy products clinical approval accounts for 1/5 of the country.

From the comprehensive ranking of the regional thermal value evaluation index of strategic emerging industries in the biomedical industry, six districts and counties in Shanghai entered the top 100, namely Pudong New Area (1st), Fengxian District (16th), Minhang District (29th), Jinshan District (36th), Jiading District (40th) and Songjiang District (69th).

So who will benefit from Shanghai's 21.5 billion yuan biomedical investment?

It can be learned from the 2024 Shanghai International Biotechnology and Pharmaceutical Seminar that in order to promote the development of more disruptive technologies, Shanghai is accelerating the establishment of biomedical industry investment fund. Shanghai Municipal Government hopes that through these funds, it can support the innovative development of the biomedical pilot industry, enhance the overall level and international competitiveness of the industry, and strengthen the linkage of investment and loan and investment and financing cooperation. Give play to the linkage role of financial funds at the two levels of urban areas and various funds, and guide capital to invest early, invest small, and invest in hard technology.

1. Realize the strategy of "Invest early and invest small" : Through early investment and support for start-ups, promote the strengthening of the industrial chain and ensure that the key links of the industry are not monopolized by foreign countries.

2. Promote merger and acquisition integration: Through merger and acquisition integration, optimize resource allocation, improve industry concentration, and enhance the core competitiveness of Shanghai biopharmaceutical enterprises.

3, attract more key investment projects: Shanghai plans to create intelligent space, and through these funds to attract more high-quality investment projects, to further improve the urban industrial structure.